IFNG

Across TCGA pan-cancer cohorts, IFNG Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IFNG data layer compared with 23 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IFNG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFNG expression acts as an unfavorable survival marker.

LIHC, BRCA, and GBM are the cancer types where IFNG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.125	0.547	<.001	21	view →
BRCA	OS	Median	II,III,IV	0.256	0.913	<.001	12	view →
GBM	OS	Median	All	0.104	0.415	.024	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IFNG–LIHC (DFS)

Open the LIHC breakdown →